Key result
PAD in HFpEF is linked to ~36% higher hospitalization risk and increased mortality.
Why the study?
Peripheral artery disease in HFpEF is associated with increased mortality risk, but the risk of individual adverse outcomes in this group is less clear.
Does peripheral artery disease increase the risk of adverse outcomes in patients with heart failure with preserved ejection fraction?
Population
3385 patients with HFpEF from the TOPCAT trial
Comparison
Presence vs absence of peripheral artery disease
Design
Cohort study
Follow-up
Median 3.4 years (IQR 2.0-4.9 years)
Authors
Loading...
May warrant closer monitoring for PAD in HFpEF; extends observational data but leaves open need for prospective validation.
Cohort (n=3,385)
Does peripheral artery disease increase the risk of adverse outcomes in patients with heart failure with preserved ejection fraction?
Hazard Ratio: 1.36 (95% CI 1.16–1.6)
In patients with HFpEF, the presence of peripheral artery disease is associated with a significantly increased risk of hospitalization, myocardial infarction, and mortality.
Sandesara et al. (2017) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=3,385). Peripheral artery disease (PAD) vs. No PAD was evaluated on Hospitalization (HR 1.36, 95% CI 1.16-1.60). In patients with HFpEF, peripheral artery disease was associated with an increased risk of hospitalization (HR 1.36; 95% CI 1.16-1.60) and death (HR 1.56; 95% CI 1.22-1.99) compared to no PAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: